In the early 20th century, many people died from bacterial diseases such as pneumonia and sepsis. In 1928 the bacteriologist Fleming observed that a contaminating blue-green mold dissolved colonies of staphylococci and named the active substance penicillin. Because the compound was unstable and hard to purify, clinical use stalled. During World War II, Chain and Florey improved extraction and purification methods and demonstrated dramatic therapeutic effects in animals and humans. Mortality from wound infections and pneumonia plummeted, and the drug was hailed as a “miracle cure” on battlefields and in civilian hospitals alike. The success of penicillin marked the dawn of the antibiotic era and became a major driver of public-health gains and longer life expectancy.

Fleming suggested that a substance produced by a Penicillium mold inhibited bacterial cell-wall synthesis, yet the broth was unstable and its activity hard to assay. Chain and Florey adapted techniques from their lysozyme work, combining acid precipitation with solvent extraction to obtain crystalline penicillin. They proved efficacy in a mouse septicemia model and, in 1941, reported spectacular recovery of severe infection cases at Oxford University Hospital. The U.S. government and pharmaceutical companies then cooperated to scale up production using deep-tank fermentation, corn-steep liquor media and phenylacetic-acid feeding, boosting yields enormously. Mass production dramatically reduced infection deaths among wartime casualties and was rapidly introduced into civilian medicine. Penicillin became the prototype β-lactam antibiotic, paving the way for semisynthetic derivatives such as methicillin and ampicillin. Studies of antimicrobial spectrum, pharmacokinetics and resistance mechanisms tightly linked pharmacy with microbiology and formed a cornerstone of modern clinical practice.

Fleming documented a zone of inhibition around a contaminant mold colony, but low yields and lability of the activity hampered chemical identification. Chain’s group selected Penicillium notatum NRRL 832 and combined 2-bromoacetic acid precipitation with ethyl acetate extraction, obtaining crystalline penicillin G at pH≈5.0. In a murine streptococcal septicemia model they demonstrated an LD50/ED50 ratio > 50, establishing a wide therapeutic index. Florey measured a plasma half-life of 30–40 min in first-in-human infusions and advocated continuous drip administration. From 1943 the USDA NRRL generated deep-tank–adapted hyper-producer mutants via X-ray mutagenesis, achieving titers above 2000 U mL⁻¹. By 1945 annual output reached 4.5 × 10¹⁰ units and wound-infection mortality in Allied forces fell by nearly 90 %. Early reports of β-lactamase hydrolysis stimulated structure–activity studies and side-chain modification, launching the semisynthetic pipeline. Penicillin derivatives remain first-line for surgical prophylaxis and syphilis therapy, and the development story is still cited as a paradigm for antibiotic discovery pipelines.